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OBJECTIVES:Multiple sclerosis (MS) and Alzheimer’s Disease (AD) are chronic and
progressive diseases that have the potential to impose a significant burden on both
caregivers and the immediate families of patients. Extensive literature has docu-
mented MS and AD caregiver burden on physical and mental health; but there are
no direct comparisons of MS and AD caregivers. This study examined the extent of
MS caregiver burden compared to non-caregivers and caregivers of AD patients.
METHODS:Datawere obtained from the 2009National Health andWellness Survey
administered online to a US representative adult sample (N75,000). Respondents
reported health status, quality of life, work productivity, healthcare utilization and
caregiver status. Multivariable regressions, adjusting for key characteristics (e.g.,
age, gender, marital status, depression), were conducted to explore differences
between MS caregivers (n215) vs. non-caregivers (n69,224), as well as MS care-
givers vs. AD caregivers (n1,341). Rate ratios (RR) and regression weights (b) are
reported. RESULTS: Compared to non-caregivers, MS caregivers had significantly
greater activity impairment (RR1.41; p0.01) and poorer mental (b1.44;
p0.015), physical (b1.96; p0.002), and health utility scores (b0.03;
p0.002), along with more traditional healthcare provider visits (RR1.46;
p0.0001), ER visits (RR2.16; p0.0001), and hospitalizations (RR2.20; p0.001)
after covariate adjustment. Compared to AD caregivers, MS caregivers had greater
activity impairment (RR1.29; p0.044) and more ER visits (RR1.60; p0.017) and
hospitalizations (RR1.92; p0.008) after covariate adjustment. Work productivity
differences were not observed in comparison with either group, potentially due to
the small number of employed MS caregivers in the sample (n126).
CONCLUSIONS:MS caregivers had significantly more burden compared with non-
caregivers. In addition, the results suggest an even greater burden to these indi-
viduals than observed among AD caregivers. The results of this analysis of a na-
tional survey reveal the hidden toll of those providing care for MS patients and
highlights the need to recognize their burden so that appropriate measures can be
implemented.
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OBJECTIVES: To evaluate changes in patient reported fatigue and cognitive func-
tion after one year of natalizumab treatment in multiple sclerosis (MS) patients.
METHODS: The study population consists of MS patients initiating natalizumab
treatment who agreed to participate in a 12 month longitudinal study. Patients
reported experiences with natalizumab using validated patient-reported outcome
(PRO) measures prior to natalizumab treatment initiation (BL) and after 3rd, 6th and
12th infusion. The current analysis reports change in fatigue and cognition from
baseline through the 12th natalizumab infusion. Fatigue was measured by the
5-question Modified Fatigue Impact Scale-5 (MFIS-5, score range 0-20) with lower
scores indicating lower impact of fatigue on physical, cognitive, and psychosocial
functioning; cognitive functionwasmeasured by the 6-questionMedical Outcomes
Study Cognitive Functioning Scale (MOS-Cog Scale, score range 6-36) with higher
scores indicating better reasoning skills, memory, concentration, ability to start
several actions at one time and ability to react to what is said or done. Regression
analysiswas used to control for BL covariates such as age, years sinceMSdiagnosis,
number of natalizumab infusions received, disability and functional status, num-
ber of MS drugs used prior to natalizumab and comorbidity burden. RESULTS:Data
for 324 patients who completed the BL through 12th infusion assessments are re-
ported. Themean age was 46.5 (SD10.4) and themajority of patients were female
(77.8%). The mean number of years since MS diagnosis was 10.16 (SD8.23). On
average, MFIS scores decreased significantly (BL 12.362.18; 12th infusion score
11.162.18, p0.001) and MOS-Cog scores increased significantly over time (BL
25.121.51; 12th infusion score 26.191.97, p0.001) after controlling for
covariates. CONCLUSIONS: MS patients reported improvements in fatigue and
overall cognitive function after one year of natalizumab treatment.
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OBJECTIVES: There is abundant evidence that individuals with Multiple Sclerosis
(MS) have compromised quality of life (QOL) and work productivity, and increased
healthcare resource use compared to individuals without MS. The possible associ-
ation between subjects’ self-reported severity of disease and these variables in an
MSpopulation has only recently been explored. Patient perceptions of disease have
been increasingly recognized as an important factor in healthcare resource use.
The objective of this study was to analyze the association between perceived se-
verity of disease (mild, moderate, or severe) and symptoms, quality of life, work
productivity, and healthcare resource use in individuals with MS.METHODS: Data
from respondents reporting anMS diagnosis were obtained from the 2009 National
Health andWellness Survey (NHWS), an Internet-based annual study of the health-
care attitudes and behaviors of a US representative adult sample. The survey in-
cluded questions about demographics, disease severity, symptoms, quality of life,
work productivity, and healthcare resource use. RESULTS: In the 2009 NHWS
study, 536 reported an MS diagnosis. MS respondents characterized the severity of
their disease as follows: mild (n206; 38.4%), moderate (n268; 50%); and severe
(n62; 11.6%). There were no differences in the number of years since diagnosis
among the groups but there were significantly more men in the severe group. As
perceived severity increased among MS patients (mild, moderate, severe), symp-
tom severity generally increased, QOL decreased (SF-12 Physical Component
Score), percent with full-time employment decreased, loss of work productivity
and presenteeism increased among those reporting employment and healthcare
resource use increased (ER visits and hospitalizations). CONCLUSIONS: Generally,
those withmore severe illness reported greater impairment. However, for many of
the variables examined, more significant differences were found between patients
who perceive their disease severity as mild and moderate than those patients
reporting moderate and severe disease severity.
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OBJECTIVES: This study evaluated and examined the relationship between parent-
ing stress in caring for children diagnosed with a neuro-developmental disorder.
METHODS: A cross-sectional study was conducted by using a self-administered
questionnaire distributed through schools that provide services for children with
developmental disorder. Parents with children aged 3-18 years and diagnosedwith
a neuro-developmental disorder were requested to complete the survey. Previ-
ously validated scales, the Parenting Stress Index (PSI) and the Columbia Impair-
ment Scale (CIS) were used along with scales to measure parent and child’s char-
acteristics. Data was coded and analyzed using SAS v9.2 by performing descriptive
and regression analyses. RESULTS: A total of 150 surveys were received from 4
schools net response rate (26.5%). Themean parent’s age was 45.7(6.4) years with
mothers being higher portion of respondents (84%) and most (90%) were married.
Mean PSI reported was 96.9(23.9) and clinically significant (85). Higher PSI was
attributed to the difficult child (DC) subscale (35.610.4) followed by parental dis-
tress (PD) subscale (31.89.3) and the parent-child dysfunctional interactions
(PCDI) subscale (30.28.5). Reliability coefficients for the PSI was high (0.91), includ-
ing the subscales (DC0.85, PD0.87, and PCDI0.8). Mean summary score for CIS
was 19.1(10.7) with a reliability coefficient of 0.9. A multiple regression analysis
indicated a positive relationship of PSI with developmental impairment (CIS,
1.43 p0.0001) after controlling for child’s characteristics (age, gender, diagno-
sis, number of children, child with similar diagnosis, relationship of parent) and
parent’s characteristics (age, race, education, employment status, income and ex-
isting disorder). CONCLUSIONS: Children with severe developmental impairment
may lead to greater stress for parents. Untreated stress can cause diseases, such as
heart diseases and depression. Interventions controlling stress is the key to im-
proving parents’ quality of life for those that care for children with neuro-develop-
mental disorders.
PND42
THE ASSOCIATION BETWEEN PARKININSON’S DISEASE QUESTIONNAIRE (PDQ)
SCORES WITH CARER STRAIN AND QUALITY OF LIFE
Jenkinson C1, Peters M2, Fitzpatrick R2, Churchman D3
1University of Oxford, Health Services Research Unit, Oxford, Oxfordshire, UK, 2University of
Oxford, Oxford, Oxfordshire, UK, 3Isis Innovation Ltd., Oxford, Oxfordshire, UK
OBJECTIVES: The impact of Parkinson’s disease (PD) on the quality of life of both
patients and their carers has not been well documented. This study describes the
health status of both PD patients and caregivers asmeasured on a genericmeasure
of health status (SF-12), and then explores to what extent patient self-reported
health, as measured on the disease-specific Parkinson’s Disease Questionnaire
(PDQ-39), is associated with carer strain and self-reported quality of life.
METHODS:Apostal surveywas carried out of both patients and caregivers through
local branches of Parkinson’s UK. Questionnaire packs were sent to those on the
database with a diagnosis of PD. Patients were asked to give the carer question-
naire to theirmain caregiver, if they had one. RESULTS: Results suggest that PD has
substantial adverse effects on both the physical (measured by the Physical Com-
ponent Summary, PCS) andmental well-being of patients (measured by theMental
Component Summary, MCS) when compared with population norms. Most strik-
ingly PD patients PCS scores fall within the lowest 10% of results, compared with a
wider general population sample. While carer physical health was not found to be
substantially different from that of the general population, emotional health was
severely compromised with a MCS score that places them in the lowest 22% of the
population. Regression analysis suggests that the major predictors of carer strain
are the PDQ scales of mobility and social support. Carer strain was found to be
closely associated with carer mental health. CONCLUSIONS: PD impacts on the
well being of both patients and caregivers; the data provide evidence that the
health status of the patient, in particular their physical health, has a significant
impact on the well-being of their caregivers.
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OBJECTIVES: To describe key characteristics of members of the online, USA-based
PatientsLikeMe® Epilepsy Community, by comparison with a widely-used USA
claims database, PharMetrics®, and to assess the impact of epilepsy on patients’
lives using patient-reported data, collected through PatientsLikeMe®. METHODS:
The PatientsLikeMe® Epilepsy Community allows patients with epilepsy to record
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